Mineralys Therapeutics, Inc. (NASDAQ:MLYS) showed up in the 13F filings of 218 institutional investors as of December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 31 Mar, 2026 | 7,903,838 | 7,903,838 | 0.00% | $214,114,971.00 |
| RA CAPITAL MANAGEMENT, L.P. | 31 Mar, 2026 | 7,692,750 | 369,000 | 5.04% | $208,396,598.00 |
| Samsara BioCapital, LLC | 31 Mar, 2026 | 5,871,018 | 0 | 0.00% | $159,045,878.00 |
| FMR LLC | 31 Mar, 2026 | 4,861,104 | -196,405 | -3.88% | $131,687,318.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 4,481,582 | 153,904 | 3.56% | $121,406,057.00 |
| WELLINGTON MANAGEMENT GROUP LLP | 31 Mar, 2026 | 3,359,068 | 2,574,801 | 328.31% | $90,997,151.00 |
| State Street Corp | 31 Mar, 2026 | 2,935,940 | -249,059 | -7.82% | $79,534,615.00 |
| Caligan Partners LP | 31 Mar, 2026 | 2,772,654 | 0 | 0.00% | $75,111,197.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 2,454,363 | 2,454,363 | 0.00% | $66,488,694.00 |
| Laurion Capital Management LP | 31 Mar, 2026 | 2,232,040 | -1,194,930 | -34.87% | $60,465,964.00 |
| ORBIMED ADVISORS LLC | 31 Mar, 2026 | 2,052,900 | 1,072,500 | 109.39% | $55,613,061.00 |
| Point72 Asset Management, L.P. | 31 Mar, 2026 | 1,911,433 | 704,213 | 58.33% | $51,780,720.00 |
| Franklin Resources Inc | 31 Mar, 2026 | 1,784,662 | -4,085 | -0.23% | $48,346,494.00 |
| Andera Partners | 31 Mar, 2026 | 1,591,917 | 0 | 0.00% | $43,125,032.00 |
| SR ONE CAPITAL MANAGEMENT, LP | 31 Mar, 2026 | 1,563,966 | 0 | 0.00% | $42,367,839.00 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 1,538,662 | 0 | 0.00% | $41,682,354.00 |
| Polar Capital Holdings Plc | 31 Mar, 2026 | 1,500,749 | 99,608 | 7.11% | $40,655,290.00 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 31 Mar, 2026 | 1,343,313 | 1,343,313 | 0.00% | $36,391.00 |
| SPHERA FUNDS MANAGEMENT LTD. | 31 Mar, 2026 | 1,339,971 | 890,968 | 198.43% | $36,299,814.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 1,301,135 | 43,553 | 3.46% | $35,254,696.00 |